Optisure Leads (LDA210, LDA210Q, LDA220Q, LDP210Q, LDP220Q, LDA230Q, LDP230Q); Quartet Leads (1456Q, 1457Q, 1458Q, 1456Q
ABBOTT MEDICAL · Decision date Apr 24, 2026
What did the FDA decide?
FDA records P030054/S444 as a supplement to PMA P030054, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 24, 2026.
FDA approval order statement
tooling changes and added in-process inspections for lead manufacturing
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P030054/S444
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- NIK
- Decision code
- OK30
- Decision date
- Apr 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).
- Applicant
- Abbott Medical
- Product code
- NIK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P030054/S438 · Related supplement
Avant (CDHFA700Q, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800T CDHFA600Q, CDHFA600T); Gallant (CDHFA500Q, CDHFA500T);
P030054/S436 · Related supplement
Quartet 1456Q, 1457Q, 1458Q, 1458QL; Avant HF CDHFA700B, CDHFA700D, CDHFA700Q, CDHFA700T; Gallant HF CDHFA500B, CDHFA
P030054/S439 · Related supplement
Quartet and QuickFlex µ Left Heart Leads
P030054/S441 · Related supplement
Avant (CDHFA700Q, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800T CDHFA600Q, CDHFA600T); Gallant (CDHFA500Q, CDHFA500T);
P030054/S435 · Related supplement
Quartet; QuickFlex Micro
P030054/S444 received
Application receipt date recorded by FDA.
P030054/S443 · Related supplement
Avant (CDHFA700Q, CDHFA700B, CDHFA700D, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800B, CDHFA800D, CDHFA800T); Gallant (
P030054/S442 · Related supplement
Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+
P030054/S444 · FDA decision
30-Day Notice
P030054/S445 · Related supplement
Avant (CDHFA700Q, CDHFA700T, CDHFA700D); Neutrino NxT (CDHFA800Q, CDHFA800T, CDHFA800B, CDHFA800D, CDHFA600Q, CDHFA600T,
P030054/S440 · Related supplement
Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+
P030054/S446 · Related supplement
Avant (CDHFA700Q, CDHFA700B, CDHFA700D, CDHFA700T); Neutrino NxT (CDHFA800Q, CDHFA800B, CDHFA800D, CDHFA800T, CDHFA600Q,
Timeline entries are records held by MedtechLedger for P030054. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030054
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Aug 4, 2025 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 27, 2025 | FDA | |
Quartet and QuickFlex µ Left Heart LeadsP030054/S439 | ABBOTT MEDICAL | PMA supplement | Nov 20, 2025 | FDA |
| ABBOTT MEDICAL | PMA supplement | Feb 13, 2026 | FDA | |
Quartet; QuickFlex MicroP030054/S435 | ABBOTT MEDICAL | PMA supplement | Feb 19, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Mar 27, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Apr 24, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jul 9, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Jul 21, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Aug 12, 2026 | FDA |
Explore the linked device profile
Other records with product code NIK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Sep 25, 2026 | FDA | |
Tachy Pulse GeneratorsP010012/S612 | Boston Scientific Corp | PMA supplement | Aug 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 15900 Valley View Ct., Sylmar, CA, 91335
Sources and methodology
- Original FDA record: P030054/S444
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






